# European Urology

Source: https://onco.cc/journals/european-urology/  
OnCo record `european-urology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.

## Summary

Publishes the EAU guidelines, prostate-cancer screening and active-surveillance cohorts, PSMA PET and radioligand studies, and secondary analyses of the large phase 3 trials in bladder and kidney cancer. Hybrid access via Elsevier; sister titles include European Urology Oncology and European Urology Open Science.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Eur Urol
- Publisher: Elsevier
- Scope: urology
- Access: hybrid

## Sources

- EAU Guidelines: https://uroweb.org/guidelines

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- key papers: [A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer](https://onco.cc/key-papers/paper-hugosson-eur-urol/), [ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients](https://onco.cc/key-papers/paper-arches-eur-urol-2026-update/), [Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial](https://onco.cc/key-papers/paper-aranote-eur-urol-2026/), [Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging](https://onco.cc/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/), [EAU-ASCO collaborative guideline on penile cancer, 2023 update](https://onco.cc/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/), [Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial](https://onco.cc/key-papers/paper-boeve-eur-urol/), [EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer](https://onco.cc/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/), [European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)](https://onco.cc/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/), [Overdiagnosis and overtreatment of prostate cancer](https://onco.cc/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/), [Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study](https://onco.cc/key-papers/paper-nct02861573-eur-urol-2022/), [PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate](https://onco.cc/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/), [WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours](https://onco.cc/key-papers/paper-who-2022-gu-moch-eur-urol-2022/), [Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression](https://onco.cc/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/)
- people: [Andrea Necchi](https://onco.cc/people/andrea-necchi/), [Arnaud Méjean](https://onco.cc/people/arnaud-mejean/), [Declan G. Murphy](https://onco.cc/people/declan-murphy/), [Louise Emmett](https://onco.cc/people/louise-emmett/), [Shahrokh F. Shariat](https://onco.cc/people/shahrokh-f-shariat/), [Silke Gillessen](https://onco.cc/people/silke-gillessen/)

---
JSON: https://onco.cc/api/v1/entities/european-urology.json